These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4946082)

  • 1. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
    Muggia FM; Selawry OS; Hansen HH
    Cancer Chemother Rep; 1971 Dec; 55(5):575-81. PubMed ID: 4946082
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.
    Dombernowsky P; Nissen NI; Larsen V
    Cancer Chemother Rep; 1972 Feb; 56(1):71-82. PubMed ID: 4624138
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours.
    Br Med J; 1972 Jun; 2(5816):744-8. PubMed ID: 4556544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review.
    Goldsmith MA; Carter SK
    Eur J Cancer (1965); 1973 Jul; 9(7):477-82. PubMed ID: 4609765
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
    Luce JK; Thurman WG; Isaacs BL; Talley RW
    Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
    [No Abstract]   [Full Text] [Related]  

  • 6. 4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action.
    Stähelin H
    Eur J Cancer (1965); 1970 Aug; 6(4):303-11. PubMed ID: 4991932
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical experience with mitomycin C (NSC-26980).
    Whittington RM; Close HP
    Cancer Chemother Rep; 1970 Jun; 54(3):195-8. PubMed ID: 4334088
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.
    Sklansky BD; Mann-Kaplan RS; Reynolds AF; Rosenblum ML; Walker MD
    Cancer; 1974 Feb; 33(2):460-7. PubMed ID: 4812764
    [No Abstract]   [Full Text] [Related]  

  • 9. SPI and SPG in the treatment of advanced malignant lesions.
    Grewal TS; Samual KC; Sachdev DL; Rastogi DC
    Int Surg; 1967 Oct; 48(4):360-7. PubMed ID: 6050546
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076).
    Vaitkevicius VK; Reed ML
    Cancer Chemother Rep; 1966 Nov; 50(8):565-71. PubMed ID: 5978729
    [No Abstract]   [Full Text] [Related]  

  • 11. [Isolation and antimitotic activity of lactones extracted from Podophyllum emodi].
    Sánchez-Parareda J; Llombart A; Gaviñá F; Pérez-Minguez F
    Rev Esp Fisiol; 1970 Sep; 26(3):257-68. PubMed ID: 5488855
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cancer of the esophagus: treatment with the cytostatic agents SP-G and SP-I].
    Guida Filho B; Mirra AP
    Rev Paul Med; 1968 Feb; 72(2):49-54. PubMed ID: 5739063
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical findings in podophyllotoxin derivatives (SP-I-SP-G) in malignant tumors].
    Ohara H; Noto J; Kihara A; Noguchi H; Ishii Y
    Gan No Rinsho; 1968 Feb; 14(2):96-100. PubMed ID: 5244790
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.
    Felix W; Senn HJ
    Cancer Chemother Rep; 1975; 59(4):737-42. PubMed ID: 1100224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies in sugar chemistry. VII. Glucuronides of podophyllum derivatives.
    Nudelman A; Ruse M; Gottlieb HE; Fairchild C
    Arch Pharm (Weinheim); 1997 Oct; 330(9-10):285-9. PubMed ID: 9396386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancer of the esophagus - treatment by cytostatics SP-G and SP-I. Previous communication].
    Guida Filho B; Mirra AP
    Hospital (Rio J); 1967 Aug; 72(2):633-40. PubMed ID: 5302562
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of Proresid on the growth and formation of metastases of the RBI-sarcoma in rats].
    Svec F; Altaner C
    Med Klin; 1968 Dec; 63(52):2119-25. PubMed ID: 5729222
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
    Kingra GS; Comis R; Olson KB; Horton J
    Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
    Luce JK; Bodey GP
    Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
    Gottlieb JA; Guarino AM; Call JB; Oliverio VT; Block JB
    Cancer Chemother Rep; 1970 Dec; 54(6):461-70. PubMed ID: 4946015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.